Important information for patients

Carry this card with you at all times.
Show it to any doctor who sees you and when you go to the hospital. Tell any healthcare professional who sees you that you have been treated with ciltacabtagene autoleucel. You may either be admitted to hospital or expected to stay local to the CAR-T treatment centre for at least 4 weeks after you are given ciltacabtagene autoleucel.[1]

Scan to view the Patient Information Leaflet

1. Electronic Medicines Compendium. CARVYKTI® Patient Information Leaflet September 2025. Available at: https://www.medicines.org.uk/emc/product/100341/pil (last accessed May 2026).

Emergency contact

Patient carer's name: _____

Patient's carer's phone number: _____

Healthcare professional's name: _____

Healthcare professional's phone number: _____

CAR-T centre address: _____

CAR-T centre phone number: _____

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card website www.mhra.gov.uk/yellowcard, the free Yellow Card app or by calling 0800 731 6789 for free. Adverse events and pregnancies should also be reported to Johnson & Johnson Innovative Medicine on 01494 567447 or at dsafety@its.jnj.com.

CARVYKTI®▼
(ciltacabtagene autoleucel)

Patient card

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Patient's name (PRINT):

Johnson&Johnson

CP-570963 | May 2026

Important information for patients

Do not drive or use tools or machines until at least 8 weeks after ciltacabtagene autoleucel infusion.[1] If you experience any newly occurring symptoms, especially any of the symptoms listed on this card, please immediately notify your physician, your treating healthcare professional or any healthcare professional available. Ciltacabtagene autoleucel can cause serious side effects in different parts of your body.[1] These symptoms can be life threatening or even fatal and need to be addressed immediately.[1] Symptoms that appear mild may quickly worsen.[1] Symptoms may be delayed and may occur weeks after your infusion.[1]

1. Electronic Medicines Compendium. CARVYKTI® Patient Information Leaflet September 2025. Available at: https://www.medicines.org.uk/emc/product/100341/pil (last accessed May 2026).

Call your treating healthcare professional straight away if you have any of these symptoms:

Cytokine release syndrome (CRS)[1]
- Fever (38 °C or higher)
- Chills
- Fast heartbeat
- Difficulty breathing
- Feeling dizzy or lightheaded

Neurological toxicity[1]
- Feeling confused
- Feeling less alert, disorientated, anxious or having memory loss
- Having difficulty speaking or slurred speech
- Slower movements or changes in handwriting

1. Electronic Medicines Compendium. CARVYKTI® Patient Information Leaflet September 2025. Available at: https://www.medicines.org.uk/emc/product/100341/pil (last accessed May 2026).

Information for healthcare team to fill in

Please give this card to your CAR-T healthcare team to fill in the information and return to you.

INFUSION DATE ON

_____

this patient received ciltacabtagene autoleucel, which is a chimeric antigen receptor T cell therapy (CAR-T cell therapy) for multiple myeloma.

Batch LOT ID number (PRINT)

_____

Important information for healthcare professionals

This patient has received an engineered autologous T cell immunotherapy product that can lead to severe and even fatal cytokine release syndrome (CRS) and neurological toxicity.[1] CRS may involve any organ system. Assess the patient for signs and symptoms of CRS and neurological toxicity. See Summary of Product Characteristics for full details. **Before providing any treatment, contact the primary healthcare professional immediately at the number on the front of the card. This patient should not donate blood, organs, tissues or cells for transplantation.**

1. Electronic Medicines Compendium. CARVYKTI® Patient Information Leaflet September 2025. Available at: https://www.medicines.org.uk/emc/product/100341/pil (last accessed May 2026).

Scan to view the
Patient Information Leaflet

CP-570963 | May 2026

Important safety information for patients taking CARVYKTI® ▼ (ciltacabtagene autoleucel).

This card contains important safety information you need to be aware of when receiving treatment with CARVYKTI®.

Carry this card with you at all times and show it to any doctor who sees you and when you go to the hospital.